Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SpagoPix - Spago Nanomedical

Next Previous
Drug Profile

SpagoPix - Spago Nanomedical

Alternative Names: SN132D

Latest Information Update: 28 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Spago NanoMedical
  • Class Contrast media; Diagnostic agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Magnetic resonance imaging enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Endometriosis
  • No development reported Breast cancer

Most Recent Events

  • 28 Dec 2024 No recent reports of development identified for phase-I development in Breast-cancer(Diagnosis) in Sweden (IV, Injection)
  • 12 Sep 2023 Spago Nanomedical completes phase-II trial in Endometriosis (Diagnosis) in Sweden (IV) (EudraCT2022-000652-11) (NCT05517447)
  • 28 Jun 2023 Adverse events data from phase-IIa SPAGOPIX-02 trial in Endometriosis released by Spago Nanomedical

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top